What should you know about BRAF-negative melanoma?

BRAF-negative melanoma does not have a detected BRAF gene change, so treatment planning relies on the tumour stage, other clinical findings, and therapies that do not require a BRAF mutation. The result is a feature of the melanoma cells, not a measure of how you feel and not, by itself, a complete description of the cancer. Your pathology and oncology teams interpret it alongside the biopsy report, examination, scans when needed, and lymph-node assessment.

BRAF is a gene involved in signals that can encourage cells to grow. A laboratory test on melanoma tissue looks for particular BRAF changes, commonly called mutations. A negative result means that the tested sample did not show the BRAF change the test was designed to detect. It does not mean that no genetic changes exist, and it does not establish the stage or outlook on its own.

The result can help narrow the treatment choices. Medicines designed to block BRAF, often together with another pathway blocker, are generally considered only when the relevant mutation is present. For BRAF-negative disease, the team may discuss surgery, immunotherapy, or other options according to whether the melanoma is confined to the skin, involves nearby lymph nodes, or has spread elsewhere.

Ask which test was used, whether the sample was adequate, and whether any additional molecular testing is relevant to your treatment plan. Confirm the stage and the next decision separately: an early melanoma may be managed with surgical removal, while lymph-node findings or spread can lead to a wider discussion about systemic treatment. A sentinel lymph node biopsy may be offered in selected situations to check the first draining lymph node.

Bring your pathology report and a list of medicines to the appointment. If immunotherapy is discussed, ask about the intended benefit, possible immune-related effects, and who to contact if new symptoms appear. Keep every planned review, because follow-up is used to examine the skin, lymph-node areas, treatment effects, and any new concern over time.

Contact your melanoma team promptly if a treated area changes, a new or changing mole appears, or you notice a firm lump near the scar or in a nearby lymph-node area. Seek urgent medical help for new severe headache, seizure, confusion, fainting, sudden weakness, or trouble speaking. These symptoms can have many causes, but neurological changes need prompt assessment, particularly in someone being monitored for melanoma spread.

During immunotherapy, report new or worsening breathlessness, persistent diarrhoea, severe abdominal pain, yellowing of the skin or eyes, marked weakness, or a widespread rash without waiting for the next routine visit. Do not stop or restart cancer treatment on your own; use the contact instructions from your treating team.

Useful questions include: What stage is my melanoma, and what findings determine it? What exactly did the BRAF test examine? Is another test needed? Is surgery enough for the current stage? Would immunotherapy be appropriate, and what warning symptoms should I report? How often will my skin and lymph-node areas be checked, and which symptoms should trigger an earlier appointment?